Breaking Finance News

A statement released earlier today by Goldman Sachs about Concordia Healthcare Corp (TSE:CXR) bumps down the target price to $5.00

Yesterday Concordia Healthcare Corp (TSE:CXR) traded -3.48% lower at $6.37. The company’s 50-day moving average is $11.35 and its 200-day moving average is $27.01. The last stock close price is down -76.42% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 599,891 shares of the stock were exchanged, down from an average trading volume of 847,568

Goldman Sachs dropped the price target of Concordia Healthcare Corp (TSE:CXR) to $5.00 reporting a possible downside of -0.22%.

Previously on 09/26/2016, RBC Capital Markets reported about Concordia Healthcare Corp (TSE:CXR) raised the target price from $0.00 to $18.00. At the time, this indicated a possible upside of 1.71%.

See Chart Below

Concordia Healthcare Corp (TSE:CXR)

Concordia Healthcare Corp has a 52 week low of $5.80 and a 52 week high of $61.66 The company’s market cap is currently $0.

In addition to Goldman Sachs reporting its target price, a total of 10 firms have reported on the stock. The consensus target price is $18.43 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Concordia Healthcare Corp (TSE:CXR)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *